A retired Navy officer has been arrested in Kerala after excise officials seized ganja and cannabis plants from his residence.
A retired Navy officer has been arrested in Kerala after excise officials seized ganja and cannabis plants from his residence.
'We could well be in a world where AI already has these dangerous capabilities and that is why there is a need for careful scientific evaluation to determine the risk and capabilities of these machines.'
Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.
Chhattisgarh Chief Minister Vishnu Deo Sai has ordered strict action against illegal opium farming after several cases surfaced in the state. The government has instructed departments to investigate and ensure stringent action against those involved.
Only a couple of specialty wire services in the US picked up this news; the mainstream press ignored what appears to be a marked -- and dramatic shift -- in the approach to drug discovery. What we are seeing is the first big bang contribution to open source drug discovery, an initiative to rope in researchers, universities and companies to make drug breakthroughs less expensive and time-consuming.
R&D is increasingly becoming an area of focus for Indian pharma companies and most of the big companies are spending about 6%-7% of their revenues on R&D activity.
Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday announced a shift in its United States (US) operations. The Indian pharma giant revealed that it has decided to exit the generics pharmaceutical segment in the country.
To prevent the race for superintelligence from going off the rails, OpenAI recommends shared standards and insights from frontier labs, public oversight and accountability proportional to capabilities, building an AI-resilient ecosystem, and reporting and measurement by labs and governments on AI's impact.
Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.
India's largest IT services company TCS believes that generative artificial intelligence (AI) is not just another tech cycle but a "civilisational shift" which will positively benefit every industry.
New drug discovery and contract research have taken a back seat as global drug majors have slowed down their research and development offshoring to India.
The Economic Survey on Monday said the advent of Artificial Intelligence (AI) casts a "huge pall of uncertainty" with regard to impact on workers across all skill levels. The Economic Survey 2023-24 tabled in Parliament predicted that the new-age technology, while turbocharging productivity, has the potential to disrupt employment in certain sectors. The Survey described AI as "phenomenal in its rapid pace of innovation and ease of diffusion" but also cautioned that the the future of work will be reshaped by it.
In a double-dose bid to boost growth and employment prospects, the Union Cabinet on Tuesday approved a Rs 2.07 trillion outlay for a research development and innovation (RDI) Scheme to fund private sector innovations, and an employment-linked incentive (ELI) to create over 35 million new jobs over the next two years.
Daiichi Sankyo, Japan's third-largest drug maker, has transferred six of its early drug discovery programmes in inflammatory and infectious diseases from its Japanese research & development (R&D) facilities to India.
Kenya's anti-doping agency says an Indian national was caught with "an illegal consignment of assorted performance enhancing substances" during a recent raid on prohibited drugs, conducted in collaboration with the country's Directorate of Criminal Investigations (DCI).
Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.
US giants are rushing to partner with Indian and Chinese companiestapping their brainpower and saving millions of dollars in the search for breakthrough treatments
PLSL's lead molecule under development for cancer treatment has completed two Phase-I studies.
Companies known for spending huge amounts on innovation globally have minuscule budgets for India. What's holding them back?
Pointing at the value arbitrage in drug discovery that India offered, the government has invited the United States companies to forge partnerships with domestic biotech firms for research and development.
'After the discovery of the biomarkers, Calpain and Inflammasomes, we know we have a biomarker to target.' 'That way, we can use the biomarkers for an early diagnosis of blood clotting due to hypoxia or low oxygen in the tissues, and can save a life.'
Pharma company Ranbaxy Laboratories has entered into a long-term drug discovery and development agreement with the US-based pharma company Merck in the area of anti-infective medicines. Ranbaxy could earn over $100 million on each drug developed through the collaborative research programme. The agreement, announced on Monday, calls for joint research to develop clinically validated anti-bacterial and anti-fungal drug candidates.
The numbers are the highest ever in the history of domestic drug discovery initiatives triggered by companies such as Dr Reddy's and Ranbaxy over a decade ago.
When AI is used to enhance operational efficiency, businesses can deliver the same product or service but with improved quality, faster, or even at a reduced cost
Companies are offering services in drug discovery and validation based on pathway analysis (that is, analysis of how toxic or radioactive substances reach humans), genomics (study of gene sequences in living organisms), proteomics (large-scale study of proteins) and translational research (clinical investigation with human patients or volunteers).
Major drug discovery outsourcing deals have almost dried up in the past 18 months for almost all prominent players in the area
I would like to renew our commitment to advancing the frontiers of science in drug discovery, says the chairman of Dr Reddy's Labs.
The recent pullout by ICICI Venture and Citigroup Venture from a three-year-old drug discovery partnership with Dr Reddy's Laboratories points to angel investors' growing aversion to risk in pharma and biotech firms, say experts.
The company has been developing donor-derived stem cell platforms.
The Tata group has earmarked about Rs 1,000 crore (Rs 10 billion) for investment over the next four years in Advinus Therapeutics, a joint venture floated by it and ex-Ranbaxy research head Rashmi Barbhaiya.
Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period in-between, according to data compiled from Bloomberg and company annual reports. Also, these companies more than doubled their R&D spending in absolute terms over these five years: From Rs 25,041 crore to Rs 63,072 crore. While this reflects a prioritisation of innovation, corporate R&D investment remains relatively conservative.
The review by the prime minister took note of the extraordinary coming together of academia, industry and government, combined with speedy but efficient regulatory process, an official statement said.
